Company intelligence / Profile preview

AROG Pharmaceuticals, Inc.

Dallas, Texas, United Statesarogpharma.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Late-stage biopharmaceutical company enrolling pivotal studies for crenolanib, an oral TKI with best-in-class profile for FLT3-mutated AML. Preliminary clinical data in solid tumors (gastric cancer, glioma, sarcoma, and lung cancer) have also been generated[2]. The company received FDA Fast Track Designation for crenolanib for Advanced Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene in 2016[3].

Therapeutic areas: Oncology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

crenolanib

Beyond the preview

Go deeper on AROG Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AROG Pharmaceuticals, Inc..

Explore the full profile